Mounjaro is no longer just about blood sugar and weight. FDA approval pushes Lilly into a bigger cardiovascular fight
The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.